Open Therapeutics Receives Oklahoma Medical Research Foundation’s Dormant Intellectual Property.
The intellectual property is available on the scientific collaboration platform, Therapoid™.
Minneapolis, MN– August 7, 2018 – Open Therapeutics LLC, a scientific collaboration platform company, received dormant intellectual property (IP) from the Oklahoma Medical Research Foundation (OMRF).
According to Jason E. Barkeloo, Founder and Chair of Open Therapeutics, “Open Therapeutics in-licenses and accepts dormant, orphan, and abandoned IP from institutions and organizations around the world. That IP is freely provided to scientists on the Therapoid™ platform. Along with grants, lab equipment, communication tools, manuscript development tool, career opportunities, and preprint server, researchers can collaborate with peers to advance the freely provided IP.”
The OMRF IP available in Therapoid™ ranges from proteins and a central nervous system treatment for Alzheimer’s, to novel multiple sclerosis (MS) treatments and pluripotent stem cells.
According to Jerome Hamilton, “We are pleased to represent this intellectual property from the Oklahoma Medical Research Foundation as we do our part in making the world a better place with therapeutic discoveries. Open Therapeutics will continue to add value for scientists while facilitating a world class experience as they collaborate with their peers on the Therapoid™ platform.”
The OMRF IP is listed on the Therapoid™ platform, which is in alpha release at https://Therapoid.net.
About Open Therapeutics LLC
Open Therapeutics (http://OpenTherapeutics.org) is an intellectual property firm that creates and attracts therapeutic technologies and crowdsources them for use by the global scientific community. Researchers can freely access the intellectual properties, funding, lab equipment, manuscript development tool, and preprint server to further the development of the therapeutic technologies (medical devices, pharma, diagnostics) at Therapoid™ (https://Therapoid.net). The Company is headquartered in Minneapolis, MN, with operations in Cincinnati, OH, Amman, Jordan, and Bangalore, India.
Contact: Jerome Hamilton, CEO, Open Therapeutics